MNKD — MANNKIND CORP
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 899460 ·
Last close
$3.34
Market Cap
$1.07B
52W High
$6.51
52W Low
$2.23
ADV30
3,867,967
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 109,375,000 | 79,835,000 | -835,000 | -19,032,000 | 732,304,000 | 52,929,000 | 799,501,000 |
| Mar 2026 | 90,171,000 | 72,698,000 | -2,985,000 | -16,619,000 | 744,403,000 | 52,834,000 | 803,598,000 |
| Dec 2025 | 111,955,000 | 82,282,000 | -7,690,000 | -15,948,000 | 792,182,000 | 74,882,000 | 843,204,000 |
| Sep 2025 | 82,130,000 | 61,927,000 | 18,776,000 | 7,985,000 | 494,640,000 | 127,392,000 | 539,192,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$19,267,000
Investing CF
$-292,040,000
Financing CF
$278,303,000
CapEx
$-6,116,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.07
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,231,607,000
Inventory
$44,419,000
Receivables
$43,207,000
ST Investments
$58,201,000
EBIT TTM
$-506,000
Pretax Income TTM
$-48,654,000
Interest Exp TTM
$48,148,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$393,628,992
EBITDA
$19,535,000
Free Cash Flow
$40,309,752
Enterprise Value
$1,528,478,336
Total Cash
$111,130,000
Total Debt
$433,831,008
Shares Out
321,544,484
Trailing EPS
$-0.15
Book Value
$-0.22
ROE
—
ROA
0.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 348,966,000 | 46,550,000 | 5,863,000 | 792,182,000 | 843,204,000 | -51,022,000 | 18,255,000 |
| Dec 2024 | 285,504,000 | 68,680,000 | 27,588,000 | 393,843,000 | 472,659,000 | -78,816,000 | 42,511,000 |
| Dec 2023 | 198,962,000 | 10,594,000 | -11,938,000 | 475,198,000 | 721,366,000 | -246,168,000 | 34,094,000 |
| Dec 2022 | 99,770,000 | -68,921,000 | -87,400,000 | 295,282,000 | 545,820,000 | -250,538,000 | -80,679,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.13
Max Pain — expiry 2026-11-20
max pain strike: $3.00 · spot: $3.31 · call oi: 3,025 · put oi: 2,151
Expected Move to 2026-11-20:
±$0.87
(26.28%) —
implied range
$2.44 –
$4.18
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AKTS | Aktis Oncology, Inc. | $1.04B | $19.43 | — |
| ANRO | Alto Neuroscience, Inc. | $1.04B | $26.49 | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $1.11B | $26.13 | — |
| SVRA | Savara Inc | $1.03B | $5.00 | — |
| MLTX | MoonLake Immunotherapeutics | $1.02B | $12.04 | — |
News headlines (Yahoo Finance, 1h cache)
MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses
2026-09-16 02:58 · Yahoo
MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching
2026-09-09 12:36 · Yahoo
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
2026-09-09 10:30 · Yahoo
MannKind to Present at Upcoming Investor Conferences
2026-09-02 12:30 · Yahoo
MannKind (MNKD) Could Be 48% Undervalued Following Its Afrezza And Pipeline Narrative
2026-08-29 13:05 · Yahoo
MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says
2026-08-06 16:27 · Yahoo
MannKind Q2 Earnings Call Highlights
2026-08-06 03:03 · Yahoo
Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics
2026-08-05 23:00 · Yahoo
MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates
2026-08-05 22:10 · Yahoo
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-05 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.